A Post-Market Clinical Evaluation of the ReUnion Reverse Shoulder Arthroplasty (RSA) System

Stryker Trauma and Extremities102 enrolled

Overview

This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of eighty (80) subjects will be enrolled at approximately 4-7 sites. The clinical investigation has been designed to follow the surgeon's standard of care for joint arthroplasty subjects, which entails clinical evaluation on a regular ongoing basis, or as needed should the subject become symptomatic in the treated joint.

The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the ReUnion RSA System. Efficacy/performance of the procedure will be measured the American Shoulder and Elbow Surgeons (ASES) Shoulder Score. Safety of the ReUnion RSA System will be demonstrated through reporting of device-related intra-operative and post-operative Adverse Events (AEs). Enrolled subjects will be assessed at Pre-Operative, Operative/Discharge, and at 6 Weeks, 6 Months, 12 Months, 24 Months and annually thereafter up to 10 years following the index procedure.

Study Type

OBSERVATIONAL

Enrollment

102

Conditions

Shoulder Arthroplasty

Interventions

ReUnion RSA SystemDEVICE

The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is willing to sign the informed consent. * Subject is willing and able to comply with postoperative scheduled clinical and radiographic evaluations. * Subject is male or non-pregnant female and 18 years or older at the time of surgery. * Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following: * Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis * Failed previous shoulder joint replacement Exclusion Criteria: * Subject has an active or suspected latent infection in or about the shoulder joint. * Subject has mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure or complications in postoperative care. * Subject has bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the prosthesis. * Subject has anticipated activities which would impose high stresses on the prosthesis and its fixation. * Subject is obese such that he/she produces a load on the prosthesis which can lead to failure of fixation of the device or to failure of the device itself. * Subject has concomitant disease(s) which may significantly affect the clinical outcome. * Subject has traumatic or pathologic fracture of the proximal humerus

Locations (3)

Great Plains Orthopedics

Peoria, Illinois, United States

Steadman Hawkins Clinic of the Carolinas

Greenville, South Carolina, United States

Tennessee Orthopaedic Alliance

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

American Shoulder and Elbow Surgeons (ASES) Shoulder Score

This is a mixed outcome reporting measure, applicable for use in patients with shoulder pathology regardless of diagnosis and consists of a pain visual analog scale (VAS) and 10 functional questions. The primary endpoint of the clinical investigation is to demonstrate non-inferiority of the device to the selected literature controls, as measured by the ASES Shoulder Score at 24 Months post-operative. Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.

Time frame: 24 Months

Secondary Outcomes

Safety Will be Measured by Capturing the Incidence Rate of Device-related Intra-operative Adverse Events.

Secondary outcome measures to assess safety by capturing the incidence rate of device-related intra-operative adverse events.

Time frame: 24 months

Safety Will be Measured by Capturing the Incidence Rate of Device-related Post-operative Adverse Events.

Secondary outcome measures to assess safety by capturing the incidence rate of device-related post-operative adverse events.

Time frame: 24 months

Efficacy Will be Measured by Monitoring All Implant Survivorship in All Subjects Who Have the Reverse Total Shoulder Endoprosthesis With the ReUnion RSA System.

Secondary outcome measures to assess efficacy by monitoring all implant survivorship in all subjects who have the reverse total shoulder endoprosthesis with the ReUnion RSA System.

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.